EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis

Jing Liu, Zipei Ma, Piaoran Liu, Tiezhu Yao, Jing He, Tenghui Wang, Mengjia Li, Sihan Liu, Jingtao Ma, Zhenli Li iD

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261457239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 28.05.2026. Verfasst von Jing Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China. Hauptthemen laut MEDLINE: Venous Thromboembolism, Mendelian Randomization Analysis, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foundation of Hebei Provincial Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used antidiabetic agents with established cardiorenal benefits, yet their genetic causal association with venous thromboembolism (VTE) remains uncertain.

Methods

We employed a multifaceted approach to investigate the causal relationship between SGLT2 inhibition and VTE, as well as deep vein thrombosis (DVT) and pulmonary embolism (PE). Drug-target Mendelian randomization (MR) and summary-data-based MR (SMR) analyses were conducted using genetic variants proxying SGLT2 inhibition, derived from SLC5A2 expression quantitative trait loci and glycemic traits. Positive control analyses confirmed validity using type 2 diabetes outcomes. Meta-analyses were performed across multiple independent genome-wide association study datasets. Complementary pharmacovigilance analysis was conducted using the FDA Adverse Event Reporting System (FAERS) to assess disproportionality of SGLT2 inhibitor-related VTE reports.

Results

Genetically proxied SGLT2 inhibition was significantly associated with reduced risk of type 2 diabetes (P < 0.05), validating its robustness. Most MR analyses showed no consistent causal association with VTE, DVT, or PE across datasets, and meta-analyses yielded non-significant pooled estimates (all P > 0.05). SMR analyses revealed no association between SLC5A2 expression and VTE-related outcomes (all P_SMR > 0.05). FAERS disproportionality analysis also identified no safety signals for PE (reporting odds ratio [ROR] = 0.51; 95% CI: 0.42–0.64) or DVT (ROR = 0.54; 95% CI: 0.45–0.64).

Conclusions

This integrative study provides consistent evidence that SGLT2 inhibition is not causally associated with VTE, DVT, or PE, supporting its thrombotic safety. However, generalizability to non-European populations requires future validation in diverse cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismMendelian Randomization AnalysisSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansPharmacovigilanceSodium-Glucose Transporter 2Genome-Wide Association Study

Stichwörter der Autor:innen

FAERSdeep vein thrombosismendelian randomizationpulmonary embolismsodium-glucose cotransporter 2 inhibitorsvenous thromboembolism

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSLC5A2 protein, humanSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Cardiology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
  • Graduate School, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
  • Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China.
  • Department of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.

ORCID-Profile: Zhenli Li

Förderung

  • Foundation of Hebei Provincial Department of Health

Zitieren

APA

Liu, J., Ma, Z., Liu, P., Yao, T., He, J., Wang, T., Li, M., Liu, S., Ma, J., & Li, Z. (2026). Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261457239

Vancouver

Liu J, Ma Z, Liu P, Yao T, He J, Wang T, et al. Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261457239

BibTeX
@article{Liu2026,
  author = {Liu, Jing and Ma, Zipei and Liu, Piaoran and Yao, Tiezhu and He, Jing and Wang, Tenghui and Li, Mengjia and Liu, Sihan and Ma, Jingtao and Li, Zhenli},
  title = {Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261457239}
}
Kostenlos starten →